GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $21.8 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 4.21% year-over-year to $21.8 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (up 15.56% YoY), and the FY2025 full-year result was $85.2 million, up 22.55% from the prior year.
• Depreciation & Amortization (CF) eased to $21.8 million in Q1 2026, from $23.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $43.6 million in Q4 2023 to a low of $11.4 million in Q1 2022.
• A 5-year average of $19.9 million and a median of $17.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 180.74% in 2023 and slumped 56.21% in 2024, its largest moves.
• Tracing GDRX's Depreciation & Amortization (CF) over 5 years: stood at $15.5 million in 2022, then soared by 180.74% to $43.6 million in 2023, then tumbled by 56.21% to $19.1 million in 2024, then increased by 21.21% to $23.1 million in 2025, then decreased by 5.85% to $21.8 million in 2026.
• Business Quant data shows GDRX's Depreciation & Amortization (CF) at $21.8 million in Q1 2026, $23.1 million in Q4 2025, and $21.4 million in Q3 2025.